Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Mar 30, 2018 12:18am
161 Views
Post# 27807077

RE:RE:RE:RE:RE:RE:Prometic

RE:RE:RE:RE:RE:RE:PrometicYou're wrong. Resistance can(does) cause non-response but not all non-response is caused by resistance that was my point, your thinking is too limited on this subject.

For example read this and get more informed.

https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/367/overview

Hopefully somebody will repost this for your own good.



jfm1330 wrote: You are on my ignore list. But when you are quoted by somebody else I can still read falsehoods. Resistance and not responding to a drug is the same thing. The good thing is not that they don't talk about resistance, they do in other words. The good thing is that they just say not reponding to several drugs and failing their current therapy.

Resistance to two drugs fits the several drugs definition and there is no words about three classes or several classes. So in theory a patient resistant to two drugs in the same class could be prescribed Trogarzo. It won't happen since it would make no medical and economic sense. But clearly the door is wide open for patients resistant to two drugs in two classes and resistant to other ARV drugs.

No need to answer me. You are on my ignore list.

SPCEO1 wrote:
PoorOpinion wrote:
 

TROGARZO is a drug for the treatment of human immunodeficiency virus 1 (HIV-1) infection in adults who:

  • have received several anti-HIV-1 regimens in the past, and
  • have HIV-1 virus that is not responding to many antiretroviral medicines, and
  • who are failing their current antiretroviral therapy

HIV-1 is the virus that causes AIDS (Acquired Immune Deficiency Syndrome)."

Somehow those three bullet points look even simpler than the label doc, not even a mention of resistance. The salespeople should have those tatooed on the inside of their eyelids.



 




Bullboard Posts